ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations

Heart failure patients vaccinated against influenza are at a significantly lower risk of dying, both during flu season and outside of it.

Patients with heart failure vaccinated had a 48% lower risk of death during influenza season and a 21% lower risk during the rest of the year.

Dr. Fukuta, lead investigator in this study, explained that flu vaccination of heart failure patients in Japan is not formally recommended. Larger-scale and adequately powered randomized controlled trials, such as INVESTED, will provide a definitive answer.

At the moment, with some inconsistent results, we must settle for this meta-analysis led by Dr. Fukuta, which includes 5 observational studies involving a total of 78,882 patients with heart failure. The age of patients ranged from 64 to 75 years old, and study follow-up was between 1 and 4 years.


Read also: ACC 2018 | Risk of MI in Non-Cardiac Surgeries.


There are physiopathologic reasons supporting vaccination, such as the fact that respiratory infections (including influenza) are the precipitating cause of heart failure and are associated with increased mortality. If vaccination reduces the incidence and/or severity of these respiratory infections, it will prevent heart failure exacerbations, hospitalization, and associated mortality.

Furthermore, vaccination reduces the risk of cardiovascular events, including infarction and unstable angina, in patients with coronary artery disease. There are studies showing a sixfold higher risk of infarction in the week after a flu diagnosis. In such cases, physiopathology is probably related to inflammation.

Original title: The Effect of Influenza Vaccination on Mortality and Hospitalization in Patients with Heart Failure: A Meta-Analysis.

Presenter: Fukuta H.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...